StockData
Dogwood Therapeutics, Inc. logo

Dogwood Therapeutics, Inc. (DWTX) stock

DWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$1.08+0.00 (0.00%)

Close on Nov 18, 2026Market cap $36.71MP/E –Yield –

Dogwood Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Dogwood Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$38.76M. For fiscal 2025 it was -$27.97M. The highest annual figure on record is -$5.45M in fiscal 2023.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$27.97M–
FY2024Dec 31, 2024-$12.23M–
FY2023Dec 31, 2023-$5.45M–
FY2022Dec 31, 2022-$12.32M–
FY2021Dec 31, 2021-$15.64M–
FY2020Dec 31, 2020-$10.01M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$14.06M–
Q1 FY2026Mar 31, 2026-$5.08M–
Q4 FY2025Dec 31, 2025-$3.81M–
Q3 FY2025Sep 30, 2025-$15.81M–
Q2 FY2025Jun 30, 2025-$3.92M–
Q1 FY2025Mar 31, 2025-$4.43M–
Q4 FY2024Dec 31, 2024-$7.54M–
Q3 FY2024Sep 30, 2024-$2.30M–
Q2 FY2024Jun 30, 2024-$1.07M–
Q1 FY2024Mar 31, 2024-$1.31M–
Q4 FY2023Dec 31, 2023-$1.14M–
Q3 FY2023Sep 30, 2023-$1.27M–
Q2 FY2023Jun 30, 2023-$1.48M–
Q1 FY2023Mar 31, 2023-$1.56M–
Q4 FY2022Dec 31, 2022-$2.09M–
Q3 FY2022Sep 30, 2022-$2.59M–
Q2 FY2022Jun 30, 2022-$3.67M–
Q1 FY2022Mar 31, 2022-$3.96M–
Q4 FY2021Dec 31, 2021-$4.19M–
Q3 FY2021Sep 30, 2021-$4.11M–
Q2 FY2021Jun 30, 2021-$4.28M–
Q1 FY2021Mar 31, 2021-$3.06M–
Q4 FY2020Dec 31, 2020-$6.42M–
Q3 FY2020Sep 30, 2020-$2.66M–
Q2 FY2020Jun 30, 2020-$538.38K–
Q1 FY2020Mar 31, 2020-$382.55K–

More Dogwood Therapeutics figures

See a number that looks wrong?